Atsena logo.jpg
Atsena Therapeutics to Present Positive Interim Encore Data from the Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-associated Leber Congenital Amaurosis (LCA1) at the 46th Annual Macula Society Meeting
February 08, 2023 07:30 ET | Atsena Therapeutics
DURHAM, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent...
spyglass.png
SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
February 03, 2023 11:15 ET | SpyGlass Pharma, Inc.
ALISO VIEJO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, released 6-month data from a First-in-Human glaucoma treatment trial showing...
ONL logo.jpg
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
February 02, 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
cmi_logo.png
[Latest] Global Hyaluronic Acid Market Size/Share Worth USD 2.6 Billion by 2030 at an 8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
February 01, 2023 14:30 ET | Custom Market Insights
Sandy, Utah, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hyaluronic Acid Market Size, Trends and Insights By Grade (Food, Cosmetic,...
ONL logo.jpg
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
February 01, 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Feb. 01, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Eyenovia
Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas
January 31, 2023 09:00 ET | Eyenovia
LAS VEGAS, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its...
eyenuk_logo_redesign_2017_onecolor.png
Eyenuk Secures the First European Union MDR Certification for Autonomous AI Detection of Diabetic Retinopathy, Age-Related Macular Degeneration, and Glaucoma
January 31, 2023 07:00 ET | Eyenuk, Inc.
LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Eyenuk, a global artificial intelligence (AI) digital health company, and the leader in real-world applications for AI Eye Screening™ and AI Predictive...
ONL logo.jpg
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
January 26, 2023 07:00 ET | ONL Therapeutics
ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
22157.jpg
Optometry Equipment Market Report 2022: Increasing Prevalence of Eye Conditions Bolsters Growth
January 24, 2023 10:33 ET | Research and Markets
Dublin, Jan. 24, 2023 (GLOBE NEWSWIRE) -- The "Optometry Equipment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and...
Age-Related Macular Degeneration (AMD) Market
Age-Related Macular Degeneration (AMD) Global Market Report 2022: Featuring F. Hoffman - La Roche, Bayer, Abbvie, GSK, Novartis, Regeneron Pharmaceuticals, Bausch Health & Alimera Sciences
January 24, 2023 04:48 ET | Research and Markets
Dublin, Jan. 24, 2023 (GLOBE NEWSWIRE) -- The "Age-Related Macular Degeneration (AMD) Market, Global Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis"...